Dexmedetomidine is Neuroprotective in an in Vitro Model for Traumatic Brain Injury

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2012 Apr 13

PMID 22494498

Citations 44

Authors

Marc Schoeler

Philip D Loetscher

Rolf Rossaint

Astrid V Fahlenkamp

Georg Eberhardt

Steffen Rex

Joachim Weis

Mark Coburn

Affiliations

Soon will be listed here.

Abstract

Background: The α2-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro model for traumatic brain injury.

Methods: Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway inhibitors were examined.

Results: Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum effect at a dosage of 1 μM. This effect was partially reversed by the simultaneous administration of the ERK inhibitor PD98059.

Conclusion: In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that activation of ERK might be involved in mediating this effect.

Citing Articles

Progress on the Mechanisms and Neuroprotective Benefits of Dexmedetomidine in Brain Diseases.

Tao Z, Li P, Zhao X Brain Behav. 2024; 14(11):e70116.

PMID: 39482839 PMC: 11527817. DOI: 10.1002/brb3.70116.

Regulation of I1-imidazoline receptors on the sedation effect of dexmedetomidine in mice.

Han X, Yang Z, Zhao T, Lu G, Wang Z, Wu N Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):5927-5937.

PMID: 38363351 DOI: 10.1007/s00210-024-02991-2.

Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study.

Liu S, Kelly-Hedrick M, Temkin N, Barber J, Komisarow J, Hatfield J Crit Care Med. 2023; 52(4):607-617.

PMID: 37966330 PMC: 10939970. DOI: 10.1097/CCM.0000000000006106.

The neuroprotective effect of dexmedetomidine and its mechanism.

Hu Y, Zhou H, Zhang H, Sui Y, Zhang Z, Zou Y Front Pharmacol. 2022; 13:965661.

PMID: 36204225 PMC: 9531148. DOI: 10.3389/fphar.2022.965661.

Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice?.

Ojha S, Abramson J, Dorling J BMJ Paediatr Open. 2022; 6(1).

PMID: 36053596 PMC: 9092181. DOI: 10.1136/bmjpo-2022-001460.

References

Mueller-Burke D, Koehler R, Martin L . Rapid NMDA receptor phosphorylation and oxidative stress precede striatal neurodegeneration after hypoxic ischemia in newborn piglets and are attenuated with hypothermia. Int J Dev Neurosci. 2007; 26(1):67-76. PMC: 2692732. DOI: 10.1016/j.ijdevneu.2007.08.015. View

Roehl A, Hein M, Loetscher P, Rossaint J, Weis J, Rossaint R . Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol. 2010; 10:97. PMC: 2978146. DOI: 10.1186/1471-2377-10-97. View

Coburn M, Maze M, Franks N . The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med. 2008; 36(2):588-95. DOI: 10.1097/01.CCM.0B013E3181611F8A6. View

Finley M, Fairman D, Liu D, Li P, Wood A, Cho S . Functional validation of adult hippocampal organotypic cultures as an in vitro model of brain injury. Brain Res. 2004; 1001(1-2):125-32. DOI: 10.1016/j.brainres.2003.12.009. View

Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders R, Franks N . Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004; 502(1-2):87-97. DOI: 10.1016/j.ejphar.2004.08.044. View

Stoppini L, Buchs P, Muller D . A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991; 37(2):173-82. DOI: 10.1016/0165-0270(91)90128-m. View

Loetscher P, Rossaint J, Rossaint R, Weis J, Fries M, Fahlenkamp A . Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care. 2009; 13(6):R206. PMC: 2811924. DOI: 10.1186/cc8214. View

Tasker R, Coyle J, Vornov J . The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. J Neurosci. 1992; 12(11):4298-308. PMC: 6575993. View

Adamchik Y, Frantseva M, Weisspapir M, Carlen P, Perez Velazquez J . Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. Brain Res Brain Res Protoc. 2000; 5(2):153-8. DOI: 10.1016/s1385-299x(00)00007-6. View

10.

Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E . The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003; 96(2):524-31, table of contents. DOI: 10.1097/00000539-200302000-00041. View

11.

Paris A, Mantz J, Tonner P, Hein L, Brede M, Gressens P . The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg. 2006; 102(2):456-61. DOI: 10.1213/01.ane.0000194301.79118.e9. View

12.

Toborek M, Son K, Pudelko A, King-Pospisil K, Wylegala E, Malecki A . ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons. J Cell Biochem. 2006; 100(2):279-92. DOI: 10.1002/jcb.21013. View

13.

Shen J, Wu Y, Xu J, Zhang J, Sinclair S, Yanoff M . ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci. 2009; 51(1):35-46. DOI: 10.1167/iovs.09-3544. View

14.

Dahmani S, Paris A, Jannier V, Hein L, Rouelle D, Scholz J . Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor-independent mechanism: evidence for the involvement of imidazoline I1 receptors. Anesthesiology. 2008; 108(3):457-66. DOI: 10.1097/ALN.0b013e318164ca81. View

15.

Corrigan J, Selassie A, Orman J . The epidemiology of traumatic brain injury. J Head Trauma Rehabil. 2010; 25(2):72-80. DOI: 10.1097/HTR.0b013e3181ccc8b4. View

16.

Dahmani S, Rouelle D, Gressens P, Mantz J . Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation. Anesthesiology. 2010; 112(2):373-83. DOI: 10.1097/ALN.0b013e3181ca6982. View

17.

Noraberg J, Poulsen F, Blaabjerg M, Kristensen B, Bonde C, Montero M . Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Curr Drug Targets CNS Neurol Disord. 2005; 4(4):435-52. DOI: 10.2174/1568007054546108. View

18.

. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002; 346(8):549-56. DOI: 10.1056/NEJMoa012689. View

19.

Troadec J, Marien M, Mourlevat S, Debeir T, Ruberg M, Colpaert F . Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol. 2002; 62(5):1043-52. DOI: 10.1124/mol.62.5.1043. View

20.

Hoffman W, Kochs E, Werner C, Thomas C, Albrecht R . Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology. 1991; 75(2):328-32. DOI: 10.1097/00000542-199108000-00022. View